Kornimate/medical-research-clean huggingface dataset:
evaluation of quality of life and self-assurance and social support earned for non-cellular head cancer

Conditions: Head Cancer

Summary: research objectives: * to evaluate the quality of life of patients before and after surgery for benign head tumors ( meningiomas) and malignant tumors at stage i, ii and iii, to assess whether it depends on the size of the tumor, type of tumor, malignancy and its location * evaluation of the independence of patients before and after surgery for head tumors at different stages of the disease - benign tumors (meningiomas) and malignant tumors in stage i, ii and iii, evaluation of what factors affected the different independence of patients * multidimensional evaluation of perceived social support of patients before and after surgery for head cancers - benign ( meningiomas) and malignant tumors in stage i, ii and iii, taking into account three sources of support: significant person, family and friends scientific (research) problems: - what is the quality of life of patients before and after surgery for benign ( meningiomas) and malignant head cancers at stages i, ii and iii ? is quality of life in patients with head cancer dependent on tumor size, malignancy, location or type of cancer ?


Eligibility criteria:
inclusion criteria for the study: -clinical diagnosis of head cancer study exclusion criteria: - cranio-brain injuries and inflammatory brain diseases.
efficacy study of ramosetron in the setting of hematopoietic stem cell transplantation

Conditions: Hematologic Malignancies

Summary: 1. the purpose of this study is to determine the efficacy of ramosetron for the prevention of emesis and the control of nausea and vomiting despite of the prophylactic antiemetic treatment during hematopoietic stem cell transplantation 2. the study hypothesis is that ramosetron is effective for the prevention of emesis and control of emesis and/or vomiting that develop after the prophylactic antiemetic therapy in the setting of hematopoietic stem cell transplantation


Eligibility criteria:
inclusion criteria: 1. patients undergoing hematopoietic stem cell transplantation conditioned with highly or moderately emetogenic drugs or total body irradiation (tbi) for hematologic malignancies 2. aged over 18 yrs 3. eastern cooperative oncology group (ecog) performance status 0 - 2 4. patients who are able to take oral medications 5. patients who get well-informed and sign the consent exclusion criteria: 1. patients complicating * severe hypertension (systolic blood pressure \> 210 mmhg or diastolic blood pressure \> 120 mmhg) * significant heart disease such as congestive heart failure * renal insufficiency (serum cr \>= 3.0 mg/dl) * liver disease (aspartate aminotransferase (ast), alanine aminotransferase (alt) \> 3 upper normal limit; alkaline phosphatase (alp) \> 2 upper normal limit) 2. patients complicated by conditions such as gastrointestinal obstruction or active peptic ulcer causing emesis 3. patients with brain tumor, brain metastasis and epilepsy 4. patients with the history of extrapyramidal symptom 5. patients with the history of allergy to serotonin antagonists 6. pregnant or lactating women 7. patients with drug abuse or psychiatric illness, or patients who are not capable of the normal communications

Keywords: hematologic malignancies hematopoietic stem cell transplantation ramosetron emesis
a trial comparing efficacy and safety of gzr101 and idegasp in insulin naïve or insulin treated subjects with t2dm

Conditions: Type 2 Diabetes

Summary: this trial is conducted in china. the aim of the trial is to compare the efficacy and safety of gzr101 and insulin degludec/insulin aspart in insulin naïve or insulin treated subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * male or female, aged 18-75 years (both inclusive) at the time of signing informed consent. * bmi = 18.5-35 kg/m2 (inclusive) at screening. * diagnosed with type 2 diabetes mellitus for ≥ 6 months. * 7.0% ≤ hba1c ≤ 11.0% at screening. exclusion criteria: * women in pregnancy or lactation. * subjects with any malignancy diagnosed prior to screening or documented history of malignancy. * those with the following diseases within 6 months prior to screening: diabetic ketoacidosis, diabetic lactic acidosis, or hyperosmolar nonketotic diabetic coma. * subjects experiencing serious hypoglycaemic events (level 3 hypoglycaemia) within 3 months prior to screening. * subjects with with history of acute heart failure or having been hospitalized for coronary heart disease, myocardial infarction, unstable angina, or stroke within 6 months prior to screening. * known or suspected hypersensitivity to trial product(s). * participation in a clinical study of another study drug within 1 month prior to randomization.
essential coaching for every mother in tanzania

Conditions: Parenting Self Efficacy; Postpartum Depression; Postpartum Anxiety; Breastfeeding Self-Efficacy; Newborn Knowledge

Summary: the purpose of this study is to evaluate a text message intervention called essential coaching for every mother in tanzania to improve mothers' access to essential newborn care information during the immediate six-week postnatal period.

this is a 2-group parallel arm randomized controlled trial. participants will be randomized into either the intervention or a control group. no changes to in-person care will occur. this study will be conducted in dar es salaam, tanzania with mothers recruited from a tanzanian postnatal ward who have recently given birth at four different hospitals. participants in the intervention group will start receiving the essential coaching for every mother program based on their delivery date up to six weeks postpartum. mothers in the control group will not receive any text messages. both groups will be asked to complete a survey at enrolment and six-weeks postpartum. the investigators aim to recruitment 124 participants in total, 62 per group.

Eligibility criteria:
inclusion criteria: * have recently given birth within the hospital within 48 hours * have daily access to a mobile phone with text message capabilities * are over 18 years of age * speak and read english or swahili. exclusion criteria: * newborns die or are expected to die prior to leaving the hospital * they have no access to mobile phone, either personal or shared * unwilling to receive text messages * decline to participate * are experiencing major postnatal complications expected to impact learning or ability to consent while in the hospital (e.g., postpartum hemorrhage, seizures) * participated in phase i of this project.
the role of sustained inflation on short term respiratory outcomes in term infants

Conditions: Respiratory Distress Syndrome, Newborn; Transient Tachypnea of the Newborn; Respiratory Morbidity

Summary: sustained inflation (si) has been reported to be effective for reducing the need for intubation and/or invasive ventilation in preterm infants. however, it has also an important role to support the initial breaths and liquid removal from the airways. therefore, the investigators hypothesized that si performed just after birth may help to facilitate the transitional period and decrease the incidence of early respiratory morbidities such as transient tachypnea in term infants.


Eligibility criteria:
inclusion criteria: * term newborns * parental informed consent * inborn infants exclusion criteria: * major congenital/chromosomal abnormalities * lack of informed consent * outborn infants * premature infants
positron emission tomography (pet) study with [11c]azd2995 and [11c]azd2184, candidate pet ligands for β amyloid

Conditions: Alzheimer´s Disease

Summary: the study is carried out in order to investigate if \[11c\]azd2995, compared to \[11c\]azd2184, is a more suitable pet ligand for in vivo imaging of β amyloid depositions in the human brain. in the study the two pet ligands will be examined in both healthy volunteers and patients with alzheimer's disease.


Eligibility criteria:
inclusion criteria: * alzheimer´s disease patients - 50-85 years- mild to moderate ad, clinical progression of ad over 12 months. * healthy male volunteers: - age 20-50 years, body mass index: 18-30 kg/m2. * clinically normal physical findings including normal blood pressure and pulse rate. exclusion criteria: * alzheimer´s disease patients: * significant cerebrovascular disease or depression, central nervous system infarct or infection or lesions * clinically significant illness within 2 weeks before the study start. * administration of any investigational product with effect on brain beta amyloid levels within 3 months prior to study and/or participation in a pet investigation other than study d0180c00011 as part of a scientific study during the past 12 months,. * healthy volunteers; - clinically significant illness within 2 weeks before the study start, history of psychiatric or somatic disease/condition that may interfere.- first degree relative with dementia. obvious deterioration of memory functions.

Keywords: alzheimer´s disease amyloid deposits positron emission tomography phase i
safety and tolerability of egalet-002 in patients with moderate-to-severe chronic noncancer pain

Conditions: Moderate-to-severe Chronic Noncancer Pain

Summary: the purpose of this study is to evaluate the safety and tolerability of egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.


Eligibility criteria:
inclusion criteria: * is a man or woman between 18 and 75 years of age. * has a clinical history of moderate-to-severe chronic noncancer pain ≥6 months. * has required opioid therapy for at least 14 days prior to screening at a dose between 20 mg and 160 mg (inclusive) oxycodone/day (or opioid equivalent), and will, in the opinion of the investigator, continue to require opioid therapy (between 20 mg and 240 mg oxycodone/day, inclusive) for management of moderate-to-severe pain for the duration of the study. * has pain either not adequately controlled on current opioid regimen, requires a change of opioid due to tolerability of current opioid regimen or in the opinion of the investigator, would benefit from changing opioid for another reason. * has stable health, as determined by the investigator. * if female, the patient is currently not pregnant, not breast-feeding, nor attempting to become pregnant (for 30 days before screening through the duration of the study), or is of non-childbearing potential. * other criteria apply exclusion criteria: * has cancer-related pain. * is receiving \>240 mg oxycodone daily (or opioid equivalent) within 30 days before screening. * has a history of attempted suicide. * has used a spinal infusion pump within 6 months before screening. * has clinically unstable cardiac disease (including atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia) and/or respiratory disease (including chronic obstructive pulmonary disease or sleep apnea). * has positive urine toxicity screen for drugs of abuse (with the exception of prescribed medications). * has positive result for tetrahydrocannabinol (even if legally prescribed). * has current (or history of within the last 12 months) drug dependence or substance abuse disorder according to diagnostic and statistical manual of mental disorders, 5th edition, text revision criteria (excluding nicotine). * other criteria apply

Keywords: chronic pain opioid oxycodone non cancer pain moderate to severe
comparison of redo pvi with vs. without renal denervation for recurrent af after initial pvi

Conditions: Atrial Fibrillation; Arterial Hypertension

Summary: the objective of this study is to compare the elimination of atrial fibrillation in patients with recurrent atrial fibrillation despite prior pulmonary vein isolation (pvi) when undergoing repeat pvi (control) vs repeat pvi plus renal denervation.


Eligibility criteria:
inclusion criteria: * prior pvi ablation procedure for paroxysmal af within past 2 years * recurrent symptomatic paroxysmal af despite prior pvi * history of essential hypertension requiring at least 2 chronic antihypertensive medications exclusion criteria: * persistent af after prior ablation * congestive heart failure (nyha iii-iv functional class) * left ventricle ejection fraction \< 35% * left atrial diameter \>55 mm * an estimated glomerular filtration rate (egfr) \< 45ml/min/1.73m2, using the mdrd calculation * renal arteries unsuitable for rdn: 1. inability to access renal vasculature 2. main renal arteries \< 4 mm in diameter or \< 20 mm in length. 3. hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery 4. a history of prior renal artery intervention including balloon angioplasty or stenting that precludes a possibility of ablation treatment 5. multiple main renal arteries to either kidney * unwillingness to participate
effect of pulmonary rehabilitation in lung cancer survivors

Conditions: Lung Cancer; Lobectomy; Pulmonary Rehabilitation

Summary: patients who have surgery to cure lung cancer often have multiple problems at hospital discharge and later on. this includes poor exercise performance and quality of life, breathlessness, pain and tiredness. currently there is little formal physical or psychological support for such patients. this pilot study aims to investigate whether outpatient pulmonary rehabilitation (an exercise training and education programme), started within 2 weeks of hospital discharge, can lead to improvements in exercise performance and quality of life in patients who have undergone lung cancer surgery. the study will also assess whether pulmonary rehabilitation is acceptable for patients and will analyze the safety profile. the hypothesis is that patients; discharged from hospital after undergoing lung cancer surgery, have improved exercise performance and quality of life following early outpatient pulmonary rehabilitation compared with usual care.

the research question is to investigate * whether patients who have undergone curative surgical resection for lung cancer benefit from 8 weeks of early outpatient pulmonary rehabilitation (started within 2 weeks of hospital discharge). * to identify potential barriers to this approach pulmonary rehabilitation (pr) is the most effective non-pharmacological treatment for patients with chronic respiratory diseases, especially copd. many patients with lung cancer have co-existing smoking-related lung disorders such as copd. to date there have been no randomised controlled trials of pr in post-resection lung cancer survivors. however there is indirect evidence that pr may be of benefit in this patient cohort. cesario et al (2007)reported a 32% improvement in exercise capacity with in-patient pr, and spruit et al (2009) demonstrated a 43% improvement in six minute walk distance following an 8-week in-patient pr programme. however, both studies had small numbers, and no randomised control group. furthermore, inpatient pr is not an economically justifiable intervention in the nhs where emphasis is on self-management and ambulatory care.

Eligibility criteria:
inclusion criteria: * all patients undergoing lung cancer surgery with curative intent. exclusion criteria: * unstable cardiovascular disease severe musculo-skeletal problems that would limit exercise training(neuromuscular disorders, severe joint arthritis of lower limbs) severe peripheral vascular disease unable to walk 10 metres unaided patients unable to give informed consent recent (within 3 months of completing treatment) or untreated pulmonary tb, untreated/uncontrolled diabetes or epilepsy recent or recurrent untreated spontaneous pneumothorax
observational study of patients older than 60 years with acute myeloblastic leukemia

Conditions: Acute Myeloblastic Leukemia; Aged Higher Than 60 Years Old

Summary: the main objective of this observational survey is to estimate the incidence, the typology, and the evolution of patients with acute myelobalstic leukemia, aged more than 60 years old. in this age group (aged more than 60y), three groups of patients with very different response rates and late outcome can be delineated with specific standard chemotherapy.


Eligibility criteria:
inclusion criteria: * aged 60 years or more * with a morphologically proven diagnosis of aml according to who 2008 classification * not previously treated for aml * signed informed consent. exclusion criteria: * apl in the who classification. * ph1-positive aml or prior ph1-positive disease * aml evolving from a prior mpn in the who 2008 classification. * prior tumor, if not stable for at least two years, except in-situ carcinoma and skin carcinoma * ecog performance status score \> 3 * positive serology for hiv or htlv1, or active viralinfection for hbv and hbc. * severe uncontrolled infection at inclusion time. * psychiatric disease or an history of non-complianceto medical regimens or patients considered potentially unreliable. * absence of health care insurance

Keywords: aml
effect of instrument assisted soft tissue mobilization on hand post surgical scars in primary flexor tendons repair in zone v

Conditions: Hand Injuries

Summary: this study will be conducted to investigate the effect of instrument assisted soft tissue mobilization on hand post surgical scars in primary flexor tendons repair in zone v

the hand plays an important role in independent daily living and in communication with the environment. as the most mobile part of the upper extremity, the hand is actively used in everyday life and professional fields. the flexor tendons of the hand are critical for normal hand function. injury to these tendons can result in absent finger and wrist flexion, and a subsequent loss of overall hand function. the surgical techniques used to repair these tendons have improved in the past few decades, as have the postoperative rehabilitation protocols. in spite of these advances, flexor tendon repairs continue to be plagued by postoperative scar formation, which limits tendon gliding and prevents a full functional recovery. many different treatment methods can reduce the trauma and surgical scars. manual scar treatment is one of these methods. manual scar therapy to be effective requires applying physiological stimuli adequately to the phase of wound healing. scar tissue therapy is a treatment for reducing pain and functional limitations, improving pliability, reducing hyper-pigmentation, pruritus, fascial adhesions, to reduce scar thickness and smooth surface area. instrument assisted soft tissue mobilization (iastm) is a soft-tissue treatment technique where an instrument is used to provide a mobilizing stimulus to positively affect scar tissue and myofascial adhesion.

Eligibility criteria:
inclusion criteria: * both sex will be included in this research * hand scar in zone v * age varying from 20 to 40 * hand scar formed post primary flexor tendons repair exclusion criteria: * vascular injuries requiring arterial repair * soft tissue loss * fractures * tendon in-juries of other zones * preexisting problems such as arthritis limiting joint motion * unhealed wounds or age of scar under 6 weeks

Keywords: instrument assisted soft tissue mobilization primary flexor tendons repair hand post surgical scars
effects of sourdough fermented rye crisp bread on appetite and postprandial metabolic responses

Conditions: Appetite

Summary: the overall objective is to evaluate the impact of sourdough fermented crisp bread on effects on appetite and postprandial glucose and insulin responses. beneficial effects on appetite and postprandial insulin responses have been observed, particularly for unfermented rye crisp breads in a previous study. in the present study, the investigators evaluated how the intake of sourdough fermented rye crisp breads vs. unfermented rye crisp bread as well as a control refined wheat crisp bread product may affect self-rated appetite and postprandial insulin and glucose responses in healthy men and women in a meal-study. the investigators characterized intervention products with regards to microstructural and chemical features in order to elucidate underlying mechanisms for potential effects observed on appetite and postprandial metabolic responses.

two commercial whole grain rye crisp breads processed differently (unfermented and sourdough fermented) and a refined wheat control product were tested in the study. the rye crisp bread products contained similar ingredients. all products provide similar amounts of available carbohydrates (about 30g). the total amount of test product is about 50-60g. the specific primary aim of the study: to conduct a short-term breakfast intervention study in humans (n = 24) to compare the effect of 2 high-fiber rye crisp bread products processed in different ways (sourdough fermented or unfermented) and a refined wheat control crisp bread as part of a normal breakfast on self-rated appetite, postprandial glucose and insulin concentrations. difference in post-prandial insulin response between products is the primary endpoint. secondary aim (conducted if significant effects in the primary endpoint have been demonstrated): to assess changes in hormones and their relation to self-perceived satiety, hunger and desire to eat and to differences in chemical and microstructural composition of the tested foods.

Eligibility criteria:
inclusion criteria: * bmi 18.5-30 kg/m2 * fasting plasma glucose \<6.0 mmol/l, * fasting serum insulin \<11 me/l * serum tsh \<2.5 mie/l * plasma ldl \<5.3 mmol/l * fasting plasma triglycerides (p-tg) \<1.8 mmol/l * habitual consumption of breakfast, lunch and dinner exclusion criteria: * smokers * use of medications likely to affect appetite * medical conditions involving the gastrointestinal tract * gluten intolerance or food allergies * physical problems with eating * dieting or self-reported fluctuations in body weight of more than 10% three months prior to screening recent participation in a dietary study * pregnancy * lactation
long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with radiotherapy alone

Conditions: Nasopharyngeal Carcinoma (NPC); Oncology; Radiology

Summary: nasopharyngeal carcinoma (npc) is a malignant tumor primarily originating in the nasopharynx, commonly found in populations in southern china, certain regions of asia, and north africa. the main treatment for npc is primarily radiotherapy, with some patients receiving combined chemotherapy. early-stage npc patients can achieve adequate tumor control with radiation therapy alone. various studies report that the 5-year survival rate for very early-stage npc exceeds 90%. however, some stage i patients experience local recurrence or distant metastasis after treatment, indicating treatment failure. this study aims to retrospectively analyze the factors contributing to treatment failure and prognostic factors in this group of early-stage npc patients.


Eligibility criteria:
inclusion criteria: * diagnosed with nasopharyngeal carcinoma based on endoscopic pathological reports. * included early-stage patients classified as ct1-2, cn0-1, m0. * had baseline imaging (ct or mri) prior to treatment. * received definitive radiotherapy at our institution and had long-term follow-up with complete medical records. exclusion criteria: * excluded from the study are patients with local lymph node metastasis or distant metastasis (cn ≥ 2, m = 1) as determined by imaging studies. * patients who did not receive definitive radiotherapy at our institution or had incomplete medical records during long-term follow-up are also excluded. * patients diagnosed with any other primary cancer within five years prior to the diagnosis of nasopharyngeal carcinoma (excluding dcis and skin cancer) are excluded from the study.

Keywords: nasopharyngeal carcinoma early-stage radiotherapy